1月8日，益诺思涨5.19%，截至发稿，报58.18元/股，成交1.81亿元，换手率3.57%，总市值82.02亿元。 截至发稿，郑磊累计任职时间11年26天，现任基金资产总规模80.93亿元，任职期间最佳基金回报 53.42%， 任职期间最差基金回报-35.19%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，汇添富基金旗下1只基金位居益诺思十大流通股东。汇添富医药保健混合（470006）三季度 新进十大流通股东，持有股数112.15万股，占流通股的比例为1.24%。根据测算，今日浮盈赚取约 321.88万元。 汇添富医药保健混合（470006）成立日期2010年9月21日，最新规模24.86亿。今年以来收益6.72%，同 类排名749/8825；近一年收益36.03%，同类排名3440/8084；成立以来收益162.46%。 汇添富医药保健混合（470006）基金经理为郑磊。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自 ...

Group 1 - Eddie Pharmaceuticals (688488.SH) reported its Q3 2025 results on October 31, 2025, with 13 institutional investors holding a total of 216 million shares, representing 51.44% of the company's total equity [1] - The top ten institutional investors include Guangzhou Weimei Investment Co., Ltd., Weimei Investment (Hong Kong) Co., Ltd., AEGLE TECH LIMITED, and others, collectively holding 51.23% of the shares, which is a decrease of 1.26 percentage points from the previous quarter [1] Group 2 - In the public fund sector, one fund, the Xingquan Business Model Mixed (LOF) A, increased its holdings by 0.64% compared to the previous period [2] - Three public funds reduced their holdings, including Penghua Medical Technology Stock A, with a total decrease of 0.65% [2] - Three new public funds disclosed their holdings this period, including Huatai-PineBridge Medical Care Mixed, Yongying Medical Health A, and Hongtu Innovation Medical Care Stock [2]